Heparina Leo (Heparin Sodium)

Heparina Leo is indicated for several antithrombotic applications where rapid anticoagulation is required. It is administered by a healthcare professional in controlled environments.

• Prevention of venous thromboembolism in hospitalized or immobilized patients.
• Treatment of acute deep vein thrombosis to reduce clot propagation.
• Management of pulmonary embolism to restore pulmonary blood flow.
• Anticoagulation during cardiac surgery, including cardiopulmonary bypass.
• Anticoagulation support for patients undergoing hemodialysis.

Heparina Leo may cause a range of adverse reactions, most of which are related to its anticoagulant activity. Patients should be monitored for both common and serious events.

Common

• Minor bleeding at the injection site or from mucous membranes.
• Small bruising or hematoma formation.
• Transient elevation of liver enzymes.
• Mild thrombocytopenia without clinical consequences.
• Nausea or mild gastrointestinal discomfort.

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Heparin-induced thrombocytopenia (HIT) with a risk of new clot formation.
• Severe allergic reactions such as anaphylaxis.
• Spontaneous spinal or epidural hematoma.
• Acute renal impairment secondary to bleeding complications.

Before initiating Heparina Leo therapy, clinicians should assess individual risk factors and monitor patients closely throughout treatment.

• Verify baseline coagulation parameters (aPTT, PT/INR) and platelet count.
• Adjust dose in patients with renal or hepatic impairment.
• Avoid use in individuals with known hypersensitivity to heparin or pork products.
• Use caution in pregnant or breastfeeding patients; safety data are limited.
• Monitor for signs of bleeding, especially in the gastrointestinal or central nervous system.
• Educate patients about potential symptoms of HIT and advise immediate reporting.

Heparina Leo can interact with several medications that affect hemostasis or platelet function. Awareness of these interactions helps minimize adverse outcomes.

Avoid

• Concurrent use of other anticoagulants such as warfarin, direct oral anticoagulants, or low‑molecular‑weight heparins without specialist guidance.
• Combination with antiplatelet agents (e.g., aspirin, clopidogrel) that markedly increase bleeding risk.
• Administration with fibrinolytic therapy (e.g., alteplase) due to additive hemorrhagic potential.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may impair platelet aggregation.
• Certain antibiotics (e.g., ceftriaxone) that can potentiate anticoagulant effects.
• Herbal supplements such as ginkgo biloba or garlic that have mild antithrombotic properties.